Martin O’Kane PhD is Regional (Europe) Head of Regulatory Affairs Policy & Liaison at Novartis Pharmaceuticals. He is co-chair of the IFPMA workstream on radioligand therapies and vice-chair of the European Federation of Pharmaceutical Industries Associations (EFPIA) Clinical Research Excellence group (CREG). Martin has over 20 years’ experience in medicines regulation, including 17 years with the UK Medicines and Healthcare products Regulatory Agency (MHRA), the majority of which was in the clinical trials field, including scientific assessment of trial applications and development of policy, guidance, and legislation.